Aquestive Therapeutics (AQST) Q4 2025 earnings review
Anaphylm Hit With FDA Delay, But Balance Sheet Provides Essential Runway
Aquestive navigated a major setback this quarter: a Complete Response Letter (CRL) from the FDA for its lead asset, Anaphylm, which delayed the highly anticipated Q1 2026 launch. Despite this, the company posted a stable quarter for its base manufacturing business, with Q4 revenue up 10% YoY to $13.0M. The bottom line took a hit, as net loss reversed and ballooned to $31.9M due to a $13.6M one-time legal settlement. However, management fortified the balance sheet, exiting 2025 with $121.2M in cash, providing ample runway to complete the FDA-requested human factors and pharmacokinetic studies and target a Q3 2026 NDA resubmission.
🐂 Bull Case
The FDA's CRL for Anaphylm did not identify any chemistry, manufacturing, or controls (CMC) deficiencies, nor did it question the drug's clinical efficacy or safety. The requested human factors and single PK study can be conducted in parallel.
Ending the year with $121.2M in cash and securing an amendment with RTW to extend the marketing approval deadline to June 2027 removes immediate liquidity concerns and fully funds the new regulatory timeline.
🐻 Bear Case
The delay to a potential late-2026 or 2027 approval gives competitor needle-free products (like Neffy) an additional year to solidify payer contracts, change prescribing habits, and dominate market share.
A confidential legal settlement with Neurelis resulted in an unexpected $13.6M charge, inflating Q4 SG&A to $32.8M. While supposedly one-time, this drained crucial capital precisely when the company needs to fund additional FDA-mandated studies.
⚖️ Verdict: ⚪
Neutral. The FDA CRL is a severe blow to the timeline, but the specific, non-efficacy nature of the FDA's requests and the robust cash position limit the downside risk. The company is in a holding pattern until the Q3 2026 resubmission.
Key Themes
FDA Demands Human Factors & PK Studies for Anaphylm
The FDA's January 2026 CRL derailed Aquestive's primary catalyst. The agency flagged potential 'use errors'—specifically difficulty opening the primary pouch, potential film tearing, misplacement on the tongue, and premature removal. To resolve this, Aquestive must redesign the pouch (moving to a single-motion tear line) and conduct a new 48-60 subject Pharmacokinetics (PK) study to test off-label scenarios like swallowing or chewing the film.
Base Manufacturing Business Remains Stable and Growing
Manufacture and supply revenue grew 12% YoY in Q4 to $12.0M, showing a stable operational foundation. Management noted that the gradual decline in legacy Suboxone sales is successfully being offset by growth across newer collaborations, including Ondif in Brazil and Sympazan.
Macro Resilience: US-Based Supply Chain Immune to Tariffs
Management explicitly addressed macro trade concerns, confirming that as a U.S.-based manufacturer (with facilities in Indiana) holding U.S.-domiciled intellectual property, its supply chain remains largely unaffected by both implemented and proposed government tariffs, ensuring stable gross margins.
AQST-108 Advancement Offers Secondary Pipeline Value
With Anaphylm delayed, AQST-108 (topical epinephrine gel for alopecia areata) takes on increased importance. The company opened the IND in December 2025, completed Phase 1 dosing in Q1 2026, and expects a data readout in Q2 2026. This targets a $1B+ market currently dominated by systemic JAK inhibitors that carry 'black box' warnings.
Pre-Commercial Spending Continues Despite Delay
Despite the CRL, SG&A excluding legal fees still jumped to $19.6M in Q4 (from $16.0M a year prior), driven by $3.7M in commercial spending in preparation for the Anaphylm launch. Management indicates the commercial infrastructure remains 'intact', implying ongoing high burn rates to maintain this team while waiting for the 2026 resubmission.
Other KPIs
Accelerating slightly. Revenues increased 10% YoY from $11.9 million in Q4 2024. This was primarily driven by increases in manufacture and supply revenue (Ondif and Suboxone volumes), with total doses manufactured reaching 47 million in Q4 vs 43 million last year.
Reversing. SG&A more than doubled from $16.0M in 24Q4. The spike was driven entirely by a $13.6M one-time legal settlement with Neurelis, alongside an additional $3.7M in commercial pre-launch spending. Excluding the legal hit, SG&A was $19.6M.
Decelerating. Down from $57.6M in FY2024. However, FY24 included a one-time recognition of deferred revenue due to a terminated agreement. Excluding that anomaly, total revenues decreased by a modest 3% ($1.5M) for the full year, showing a stable base business.
Guidance
Stable. The midpoint of $48.0M implies roughly 8% YoY growth compared to FY2025's $44.5M. This relies entirely on the base manufacturing business and royalties, as Anaphylm launch revenues are not expected in 2026.
Accelerating (improving). This range implies a significant improvement from the $49.7M Adjusted EBITDA loss reported in FY2025. This guidance includes the costs for the Anaphylm NDA resubmission, regulatory apps in Canada/EU, and AQST-108 clinical trials, but excludes heavy Anaphylm sales and marketing launch costs.
Decelerating. Exiting FY2025 with $121.2M and guiding to $70.0M by the end of 2026 implies a net cash burn of roughly $51M for the year. This comfortably bridges the gap to the Q3 2026 Anaphylm resubmission, ensuring the company does not need to raise dilutive capital at depressed valuations in the near term.
Key Questions
Commercial Infrastructure Costs
With the Anaphylm launch delayed until at least late 2026, you mentioned the commercial infrastructure remains 'intact'. What is the quarterly carrying cost of this infrastructure, and how much flexibility do you have to dial it down if the FDA review takes longer than expected?
Neurelis Settlement Impact
You recorded a $13.6M legal expense in Q4 for the Neurelis settlement. Does this definitively conclude all litigation regarding this civil tort case, and are there any ongoing royalty or payout obligations attached to this settlement moving forward?
AQST-108 Pipeline Prioritization
With the delay in Anaphylm, will you be accelerating capital allocation toward the AQST-108 clinical program? Should the Q2 2026 Phase 1 data read out positive, are you prepared to initiate Phase 2 immediately, or will cash preservation for Anaphylm take precedence?